164 related articles for article (PubMed ID: 28086032)
21. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902
[TBL] [Abstract][Full Text] [Related]
22. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis.
Hosseini A; Masjedi A; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Anvari E; Jadidi-Niaragh F
J Cell Physiol; 2019 Jul; 234(7):9943-9955. PubMed ID: 30536402
[TBL] [Abstract][Full Text] [Related]
23. Dimethyl fumarate-associated transient bone marrow oedema syndrome.
Triplett J; Vijayan S; Prince R; Kermode A
Mult Scler; 2019 May; 25(6):876-879. PubMed ID: 30051766
[TBL] [Abstract][Full Text] [Related]
24. Listeria monocytogenes-Induced Rhombencephalitis in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate.
Ruggieri S; Logoteta A; Martini G; Bozzao A; De Giglio L
JAMA Neurol; 2018 Jun; 75(6):762-763. PubMed ID: 29610843
[No Abstract] [Full Text] [Related]
25. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
[TBL] [Abstract][Full Text] [Related]
26. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
Dello Russo C; Scott KA; Pirmohamed M
Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
[TBL] [Abstract][Full Text] [Related]
27. Real-life persistence and tolerability with dimethyl fumarate.
Sejbaek T; Nybo M; Petersen T; Illes Z
Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
[TBL] [Abstract][Full Text] [Related]
28. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.
Suneetha A; Raja Rajeswari K
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1019():15-20. PubMed ID: 26899449
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
[TBL] [Abstract][Full Text] [Related]
30. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient.
Perini P; Rinaldi F; Puthenparampil M; Marcon M; Perini F; Gallo P
Mult Scler Relat Disord; 2018 Nov; 26():68-70. PubMed ID: 30227312
[TBL] [Abstract][Full Text] [Related]
31. Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients.
Baharnoori M; Wilson R; Saxena S; Gonzalez CT; Sotiropoulos MG; Keyhanian K; Healy BC; Chitnis T
Mult Scler Relat Disord; 2021 Nov; 56():103311. PubMed ID: 34655958
[TBL] [Abstract][Full Text] [Related]
32. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Van Schependom J; Gielen J; Laton J; Nagels G
Mult Scler; 2016 Mar; 22(3):389-92. PubMed ID: 26199353
[TBL] [Abstract][Full Text] [Related]
33. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ
Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449
[TBL] [Abstract][Full Text] [Related]
34. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
[TBL] [Abstract][Full Text] [Related]
35. B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate.
Høglund RA; Polak J; Vartdal F; Holmøy T; Lossius A
Mult Scler Relat Disord; 2018 Nov; 26():90-95. PubMed ID: 30243235
[TBL] [Abstract][Full Text] [Related]
36. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.
Tremlett HL; Oger J
Mult Scler; 2004 Jun; 10(3):298-301. PubMed ID: 15222695
[TBL] [Abstract][Full Text] [Related]
37. Expanding spectrum of opportunistic infections associated with dimethyl fumarate.
Kim T; Croteau D; Brinker A; Jones DE; Lee PR; Kortepeter CM
Mult Scler; 2021 Jul; 27(8):1301-1305. PubMed ID: 33300850
[TBL] [Abstract][Full Text] [Related]
38. Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment.
Gómez-Moreno M; Sánchez-Seco VG; Moreno-García S; Cámara PS; Sabin-Muñoz J; Ayuso-Peralta L; Oreja-Guevara C; Díaz-Díaz J; Sainz de la Maza S; Costa-Frossard L; Pilo de la Fuente B; Aladro-Benito Y
Mult Scler Relat Disord; 2021 Apr; 49():102747. PubMed ID: 33524928
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with dimethyl fumarate-induced lymphopenia.
Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
[TBL] [Abstract][Full Text] [Related]
40. Dimethyl fumarate downregulates the immune response through the HCA
von Glehn F; Dias-Carneiro RPC; Moraes AS; Farias AS; Silva VAPG; Oliveira FTM; Silva CEBG; de Carvalho F; Rahal E; Baecher-Allan C; Santos LMB
Mult Scler Relat Disord; 2018 Jul; 23():46-50. PubMed ID: 29763776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
